Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 16/20 | 0.49 |
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30515825 | 0.78 | TBXAS1 (0.35) | TBXAS1IDO1CYP11B2 | |
| Hydrochloric Acid SCHEMBL9265008 | 0.72 | IDO1 (0.51) | TBXAS1IDO1CYP11B2 | |
| SCHEMBL7072277 | 0.71 | GLA (0.37) | — | |
| SCHEMBL30430738 | 0.70 | TBXAS1 (0.47) | TBXAS1IDO1CYP11B2PTGS1PTGS2 | |
| SCHEMBL9123926 | 0.69 | TBXAS1 (0.49) | TBXAS1CYP11B2PTGS1PTGS2PTGIS | |
| SCHEMBL10818 | 0.69 | CYP11B2 (0.46) | TBXAS1IDO1CYP11B2PTGS1PTGS2 | |
| SCHEMBL20295391 | 0.69 | CYP11B2 (0.46) | TBXAS1IDO1CYP11B2PTGS1PTGS2 | |
| SCHEMBL31034784 | 0.69 | CYP11B2 (0.46) | TBXAS1IDO1CYP11B2PTGS1PTGS2 | |
| SCHEMBL10980581 | 0.67 | TBXAS1 (0.97) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL18137638 | 0.67 | LCK (0.36) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110099901-B | Pyrazolo [3,4-b ] pyridines and imidazo [1,5-b ] pyridazines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-01-03 | — | — | CN | disclosed |
| EP-3558988-B1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2021-07-07 | — | — | EP | disclosed |
| EP-3558988-B1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2021-07-07 | — | — | EP | disclosed |
| US-10689379-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-10689379-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-20190352302-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-11-21 | — | — | US | disclosed |
| US-20190352302-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-11-21 | — | — | US | disclosed |
| EP-3558988-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2019-10-30 | — | — | EP | disclosed |
| US-10351561-B2 | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2019-07-16 | — | — | US | disclosed |
| US-10351561-B2 | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2019-07-16 | — | — | US | disclosed |
| US-20180179200-A1 | PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-06-28 | — | — | US | disclosed |
| WO-2018115067-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018115067-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-06-28 | — | — | WO | disclosed |
| US-20180179200-A1 | PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-06-28 | — | — | US | disclosed |
| US-20180179200-A1 | PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352302-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | PDE5A, PDE12, PDE3A | TBXAS1 882/4885IDO1 66/4885CYP11B2 81/4885 |
| US-10689379-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | PDE5A, PDE12, PDE3A | TBXAS1 882/4885IDO1 66/4885CYP11B2 81/4885 |
| US-10351561-B2 | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors | PDE5A, PDE12, PDE3A | TBXAS1 882/4885IDO1 66/4885CYP11B2 81/4885 |
| US-20180179200-A1 | PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS | PDE5A, PDE12, PDE3A | TBXAS1 882/4885IDO1 66/4885CYP11B2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.